hepatitis

2 Small Biotech Stocks Dreaming Big in Hepatitis C

Hepatitis C treatment has progressed by leaps and bounds in the past few years, and appears to be accelerating even more quickly now. Cure rates have increased, treatment times are plummeting, and side effects are falling away. Is now the time to jump into the biotechs researching new drugs?Industry Focus takes a look at Regulus Therapeutics and Achillion Pharmaceuticals […]

February 14, 2015 douglass, focus, gilead, gilead-sciences, harvoni, hepatitis, industry, major, motley, motley-fool, pharmaceuticals, sciences Comments Off read more

Biotech stocks to watch ahead of liver disease conference

The number of patients with this chronic liver disease, which can lead to permanent liver scarring, eclipses that of hepatitis C in the U.S., RBC’s Yee said. While a significant number aren’t diagnosed, “we believe, based on survey work, that there are hundreds of thousands of patients with diagnosed NASH,” and that the global market for NASH drugs may reach […]

November 7, 2014 Byunknown disease, drug, food, gilead, hepatitis, institutes, intercept, king, liver, NASH, number, skorney Comments Off read more